HomeCompareAMANF vs PFE

AMANF vs PFE: Dividend Comparison 2026

AMANF yields 4.77% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMANF wins by $48.24M in total portfolio value
10 years
AMANF
AMANF
● Live price
4.77%
Share price
$25.12
Annual div
$1.20
5Y div CAGR
76.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.29M
Annual income
$42,310,129.55
Full AMANF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AMANF vs PFE

📍 AMANF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMANFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMANF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMANF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMANF
Annual income on $10K today (after 15% tax)
$405.39/yr
After 10yr DRIP, annual income (after tax)
$35,963,610.12/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AMANF beats the other by $35,941,290.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMANF + PFE for your $10,000?

AMANF: 50%PFE: 50%
100% PFE50/50100% AMANF
Portfolio after 10yr
$24.17M
Annual income
$21,168,194.14/yr
Blended yield
87.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AMANF
No analyst data
Altman Z
5.8
Piotroski
8/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMANF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMANFPFE
Forward yield4.77%6.13%
Annual dividend / share$1.20$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR76.4%13.2%
Portfolio after 10y$48.29M$49.6K
Annual income after 10y$42,310,129.55$26,258.71
Total dividends collected$47.79M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AMANF vs PFE ($10,000, DRIP)

YearAMANF PortfolioAMANF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,541$841.30$9,153$693.39+$2.4KAMANF
2$13,950$1,600.74$8,593$849.25+$5.4KAMANF
3$18,116$3,189.71$8,336$1,066.78+$9.8KAMANF
4$26,213$6,829.05$8,437$1,384.80+$17.8KAMANF
5$44,339$16,290.39$9,013$1,875.40+$35.3KAMANF
6$92,869$45,426.22$10,306$2,680.72+$82.6KAMANF
7$256,228$156,858.39$12,820$4,101.38+$243.4KAMANF
8$987,641$713,477.10$17,673$6,826.70+$970.0KAMANF
9$5,590,631$4,533,855.81$27,543$12,591.86+$5.56MAMANF
10$48,292,105$42,310,129.55$49,560$26,258.71+$48.24MAMANF

AMANF vs PFE: Complete Analysis 2026

AMANFStock

Amano Corporation provides time information, parking, environmental, and cleaning systems in Japan, North America, and internationally. It operates through Time Information System Business and Environment System Business segments. The company's time information systems include time and attendance (T&A), payroll, human resource, and access information systems; and T&A and access information terminals, PC interfaced time recorders, time recorders, electronic time stamps, and T&A/payroll/HR cloud services. It also provides parking systems, such as gate-type, flap-lock, bicycle parking, vehicle guidance, parking lot management, and security gate systems, as well as offers parking facility data center and commissioned management services. In addition, the company offers environmental systems comprising energy and space-saving pulse-jet, all stainless steel body, and dust explosion pressure diffusion type dust collectors; electric mist collectors; dust collectors for welding work; industrial air purifiers; and volatile organic compounds removal, pneumatic powder conveying, and large-scale dust collection systems. Further, it provides cleaning systems that include compact automatic floor and ride-on automatic scrubbers; robotic vacuum, carpet, and industrial vacuum cleaners; and electrolytic water generators, electronic high-speed burnishers, hand-pushed sweepers, and floor polishers. Amano Corporation was founded in 1931 and is headquartered in Yokohama, Japan.

Full AMANF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AMANF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMANF vs SCHDAMANF vs JEPIAMANF vs OAMANF vs KOAMANF vs MAINAMANF vs JNJAMANF vs MRKAMANF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.